CD8A and neoplasm: Additionally, combination treatment with RV and PD-1 blockade led to a significant (p < 0.001) increase in IFN-γ production by tumor-specific CD8+ splenocytes, as determined by the Enzyme-Linked ImmunoSpot (ELISPOT) assay (Figure 4F,G).